Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Lorena, Fanale, Daniele, Badalamenti, Giuseppe, Barraco, Nadia, Bono, Marco, Corsini, Lidia Rita, Galvano, Antonio, Gristina, Valerio, Listì, Angela, Vieni, Salvatore, Gori, Stefania, Bazan, Viviana, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822831/
https://www.ncbi.nlm.nih.gov/pubmed/31432460
http://dx.doi.org/10.1007/s12325-019-01057-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822831/
https://www.ncbi.nlm.nih.gov/pubmed/31432460
http://dx.doi.org/10.1007/s12325-019-01057-7

Ejemplares similares